Shingrix is a recombinant vaccine against Herpes zoster. It is more effective than the previously available vaccine Zostavax.
Patient indications - all of the following:
(1) age >= 50 years of age
(2) healthy
Dosing: 2 doses, separated by 2-6 months
Vaccination is given even if:
(1) the patient has had shingles
(2) the patient has received Zostavax
where:
• Zostavax is no longer available in the United States (discontinued in 2020).
Contraindications:
(1) severe allergic reaction to any component of the Shingrix vaccine
(2) currently have shingles
(3) test negative for immunity to Varicella zoster (this is an indication for receipt of the chickenpox vaccine)
(4) a woman currently pregnant or breastfeeding
